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Abstract 
Clusters of differentiation (CD) are cell surface biomarkers that denote key biological differences between cell types 
and disease state. CD-targeting therapeutic monoclonal antibodies (mAB) afford rich trans-disease repositioning 
opportunities. Within a compendium of systemic lupus erythematous (SLE) patients, we applied the Integrated 
machine learning pipeline for aberrant biomarker enrichment (i-mAB) to profile de novo gene expression features 
affecting CD20, CD22 and CD30 gene aberrance. First, a novel relief-based algorithm identified interdependent 
features(p=681) predicting treatment-naïve SLE patients (balanced accuracy=0.822). We then compiled CD-
associated expression profiles using regularized logistic regression and pathway enrichment analyses. On an 
independent general cell line model system data, we replicated associations (in silico) of BCL7A(padj=1.69e-9) and 
STRBP(padj=4.63e-8) with CD22; NCOA2(padj=7.00e-4), ATN1(padj=1.71e-2), and HOXC4(padj=3.34e-2) with 
CD30; and PHOSPHO1, a phosphatase linked to bone mineralization, with both CD22(padj=4.37e-2) and 
CD30(padj=7.40e-3). Utilizing carefully aggregated secondary data and leveraging a priori hypotheses, i-mAB 
fostered robust biomarker profiling among interdependent biological features.  
Key words: clusters of differentiation; data re-use; trans-disease biomarker profile; relief-based machine learning; 
systemic lupus erythematosus; transcriptomics; translational bioinformatics pipeline 
Introduction and Background 
Clusters of differentiation (CD) are cell surface biomarkers that denote key biological differences between cell types 
and disease state. For each of the >400 known CDs [Engel 2015], distinct monoclonal antibodies (mABs) enable 
robust immunophenotyping [Belov 2001, Zucchetto 2011] and serve as scalable biomarkers for translational research 
[Autenrieth 2015. However, CDs are noticeably modified by upstream, interdependent biological features.  Enriching 
the perspective of CDs holds potential to identify additional novel biomarkers of cell differentiation and activation, 
and therapeutic repositioning opportunities due to availability of many FDA-approved targeted therapeutic mABs – 
scalable high-throughput in silico approaches are needed to identify interdependent features elucidating the CD 
landscape.  
B-lymphocytes malignancies and autoimmune disorders. B lymphocytes (or B-cells) are white blood cells that are 
important regulators of the human immune system and function by secreting antibodies, presenting antigen, and 
secreting cytokines to signal other cells [Pieper 2013]. B-cell dysfunction has wide reaching consequences and can 
produce a tremendous variety of disease phenotypes, ranging from lymphoma [Ondrejka 2015], autoimmune disorders 
[Lipsky 2001], and even human immunodeficiency virus pathogenicity [Moir 2008]. This study focuses on the role of 
B cells in systemic lupus erythematosus (SLE), a highly variable, incurable autoimmune disease that can affect any 
organ system in the human body. SLE is caused by improper B cell behavior, and results in self targeted immune 
response.  
Beyond motivation to elucidate novel CD upstream biology, CD biomarkers hold potential therapeutic repositioning 
opportunities as many CDs have FDA-approved targeting therapeutic mABs in both B-lymphocyte malignancies 
[Scott 2012] and autoimmune disorders [Kamal 2014].  Therapeutic mABs can be deployed for antibody-dependent 
cytotoxicity or as combination therapies enhancing sensitivity to chemotherapy agents [Simpson 2014]. Enriching the 
perspective of CDs holds potential to elucidate therapeutic repositioning opportunities due to availability of many 
FDA-approved targeted therapeutic mABs. Scalable high-throughput in silico approaches are needed to identify 
interdependent features elucidating the CD landscape.  
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Machine learning innovations enhance statistical analyses. We developed the biologically scalable integrated 
machine learning pipeline for aberrant biomarker enrichment (i-mAB) for molecular profiling of the CDs of interest 
by incorporating multiple recently developed machine learning algorithms. Relief-based algorithms, of which most 
popular method is ReliefF, are known to effectively capture complex gene-gene interactions that are important for 
distinguishing classes but often unrecognizable by other algorithms such as Random Forest [Kononenko1997, 
McKinney 2009]. MultiSURF is an extended version of Relief F that reliably computes significance of features in 
various data structures including multiple classes with class imbalance [Urbanorwicz 2017]. In updating the feature 
scores, for a particular observation, while ReliefF considers the same number of nearest neighbors in all classes, 
MultiSURF automatically computes a neighborhood radius that is flexible throughout the feature space and often 
contains different number of observations for each class. By adaptively normalizing the weights added to each features 
based on the proportion of different classes in the neighborhood of each observation, MultiSURF inherently takes into 
account the class imbalance in the data. We presented a first known application of the novel Relief-based algorithm 
MultiSURF to real-world biomedical data to identify the most predictive gene expression features in classifying 
patients and quantify their predictive power with the automated machine learning system Tree-based Pipeline 
Optimization Tool (TPOT) [Olson 2016]. Using genetic programming, TPOT optimizes a series of feature 
preprocessing techniques and machine learning models and searches for the best prediction pipeline of different 
machine learning operators with tuned hyperparameters. We used TPOT to obtain the optimal framework for the 
training data with the objective of maximizing the cross-validated balanced accuracy and reported the out-of-sample 
balanced accuracy for classifying the patient groups in the testing data. 
Study motivation. The goal of the current study was to utilize i-mAB to enrich the perspective of CDs with 
interdependent gene expression features and identify novel upstream transcriptomic biomarkers that characterize 
aberrance of CD20, CD22, and CD30 expression. In particular, our study sought to enrich the perspectives of CD20 
(MS4A1 - Membrane-spanning 4-domains subfamily A member 1), CD22 (SIGLEC2 - Sialic acid-binding Ig-like 
lectin 2), and CD30 (TNFRSF8 - Tumor necrosis factor receptor superfamily member 8), due to characteristic 
overexpression in both B-lymphocyte hematologic malignancies and autoimmune disorders. We exclusively focused 
within gene expression characterization, for the purpose of evaluating aberrant CD expression. By incorporating 
clearly defined hypotheses with machine learning applications robust to multi-collinearity, we aim to enrich our 
perspective of CD biology and potentially leading trans-disease therapeutic repositioning opportunities.  
 
Figure 1. Integrated machine learning pipeline for aberrant biomarker enrichment (i-mAB) study overview. 
(a) Compendium data assembly: Preprocess and aggregation of gene expression data from six different studies 
resulting in a compendium of 160 healthy samples, 1290 SLE samples treatment naïve, and 126 SLE samples with 
treatment. (b) Features selection stage 1: identifying predictive genes in classifying patients with SLE treatment naïve 
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using MultiSURF. (c) Feature selection stage 2: detecting genes associated with aberrant level of CDs using 
regularized logistic regression. (d)-(e) Pathway enrichment analysis and replication beyond SLE cohort.  
Methods 
Study Overview: In this study, we aimed to detect and characterize CDs-related genes among the most predictive 
genes in classifying the samples into three categories: healthy, SLE treatment naive, and SLE treatment. For editorial 
clarity, the CD nomenclature [Engel 2015] will be deployed to reference gene expression of CD20, CD22, and CD30 
within methods and results section will reference gene expression, as opposed to the more ubiquitous deployment of 
CD nomenclature in diagnostic proteomics.  After gathering the most important features (genes) for the classifier, we 
used regularized logistic regression to robustly identify genes whose expression is either convergent or divergent in 
contribution to the effect on the aberrant expression of the CDs of interest within the SLE treatment naïve group. We 
also performed a pathway enrichment analysis of these genes to gain further insights into their biological and 
functional characteristics. An overview of compendium assembly and i-mAB pipeline are shown in Figure 1; i-mAB 
packages are provided on the Breitenstein Lab GitHub page: https://breitensteinlab.github.io/i-mAB/ 
(a) SLE Compendium assembly. A compendium of health controls, treatment naïve SLE patients, and SLE patients 
exposed to various treatments was assembled using data from Gene Expression Omnibus [Barrett 2012] – representing 
our ‘SLE Compendium’. (Note: a subset of patients within the ‘treatment naïve’ group received maintenance 
immunosuppressive therapy, but were not exposed experimental treatments). This compendium encompassed human-
derived gene expression measures from 6 original studies, including: GSE11907 [Chaussabel 2008], GSE39088 
[Lauwerys 2013], GSE72747 [Ducreux 2016], GSE49454 [Chiche 2014], GSE61635 [Carpintero 2015], GSE65391 
[Banchereau 2016], GSE78193 [Welcher 2015]. Our study exclusively utilized existing, de-identified data from 
human subjects and did not require local Institutional Review Board review. Affymetrix data was processed with 
Single Channel Array Normalization (SCAN) [Piccolo 2012]. Other platform data (e.g., Agilent, Illumina) were 
quantile normalized using the Affymetrix data as a reference. Each individual dataset was scaled from 0 to 1 on a per-
gene basis before concatenating the data sets. Detailed data preprocessing and aggregation steps (including source 
code) are available at https://github.com/greenelab/rheum-plier-data. Detailed sample characteristics of the SLE 
Compendium can be found as supplementary publication [Le 2018]. 
(b) Feature selection stage 1: identifying predictive genes in classifying patients with SLE treatment naive. 
MultiSURF-guided feature inclusion. The dataset was randomly split into 80% for training and 20% for validation. 
On the training samples, we applied MultiSURF to obtain feature importance scores and extracted the p most 
predictive features (genes) that were input of the second stage of the analysis. We remarked that the rescaling of the 
importance scores to range from -1 to 1 does not affect the relative importance among features. To prevent overfitting, 
we excluded all known CDs from this first analysis step.  
Predictive power estimation with TPOT. In order to quantify the classification accuracy provided by the MultiSURF 
features, we applied TPOT on training samples to get the optimized prediction pipeline and then implemented the 
pipeline on the training set with iterative inclusion of the features with highest MultiSURF importance scores and 
reported the pipeline’s performance on the testing set. In other words, we assessed the predictive power of the p 
features by applying the recommended set of operators with increasing number of features to obtain predictions of 
patient types in the validation set. Considering the class imbalance in our compendium data, in order to properly 
evaluate the performance of each model, we calculated the values of standard accuracy (proportion of correct 
predictions), balanced accuracy (mean of sensitivity and specificity), and Kappa coefficient which is an accuracy 
measure that is scaled to expected accuracy. 
When performing feature selection among genes sampled at multiple time points, there is the potential for 
autocorrelation of the expression of genes over time.  However, our goal was to find a comprehensive list of gene 
expression features that might affect CD expression levels regardless of the sampled time point. Thus, we treated a 
given transcript’s expression at each time point as independent of other time points. This increases the power to detect 
multiple time-dependent responses. For example, a certain gene might be important because of its role in early 
response to treatment whereas another gene might be activated in a later secondary response. Choosing only one time-
point or averaging over time would decrease the power detect a variety of such gene expression signals. This is also 
the reason we did not implement popular techniques to treat data’s imbalance such as resampling or generating 
artificial samples, which do not reduce the bias toward the majority class in high dimensional data [Lusa 2013]. We 
remark that, despite having multiple time samples, some effects still might be difficult to detect because some 
individual’s genes might peak at a different characteristic time point for a given cellular response.  
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(c) Feature selection stage 2: detecting CD-related genes with regularized logistic regression. Within our SLE 
Compendium, gene expression of all known CDs, including CD20, CD22 and CD30, were categorized as ‘aberrant’ 
or ‘non-aberrant’ based on the following criteria: i) two-tailed normalization at 20th and 80th percentile of relative gene 
expression. The two tails encompassed ‘aberrant’ CD expression, whereas the middle distribution served as ‘non-
aberrant’. Based on  histogram distributions, threshold adjustment were necessary for a subset of CDs:  ii) Adjusted 
two-tail normalization (n=4) was applied when CD expression followed an apparent normal distribution, but the 
default thresholds did not satisfactorily characterize feature variation, or  iii) binarization of non-normal distributions 
(n=86) separated the expression values into low/high groups (instead of non-aberrant/aberrant) to characterize 
apparent patterns of CD expression distributions. (Note: two-tailed normalization without adjustment was applied for 
CD20, CD22, and CD30). Detailed labelling of all CD features (histograms of gene expression distribution, descriptive 
statistics of overall expression and variation within the SLE Compendium) are provided within a supplementary 
manuscript [Le 2018]. 
Elastic net was chosen for regularization of gene expression features in our second feature selection stage due to 
known robustness within bioinformatics applications using high-dimensional data with highly correlated biological 
features [Zou 2005]. We performed elastic net regularized logistic regressions on each of the categorized CD variable 
and identified a set of k features (k < p) that are associated with each CD expression among the p previously selected 
features predicting SLE treatment naïve patients (feature selection stage 1). Incorporating Lasso (L1) and ridge 
regression (L2) penalties, the elastic net simultaneously selects variables and shrinks the coefficients of correlated 
predictors. We set the hyper-parameter α=0.5 to balance the proportion of L1 and L2 penalty and tuned the 
regularization parameter λ with cross validation to obtain the best model containing the genes that are associated with 
the expression level of the CD of interest. Notably, elastic net will tend to give strongly correlated genes similar 
regression coefficients. These genes were then ranked based on the adjusted p-value resulting from their independent 
logistic regression of the CD Aberrant/Non-aberrant expression groups. Independent odds ratio for each association 
was also reported. Further, because data on gender and age are not available for two of the six studies, we did not 
correct for these covariates to preserve the power of the analysis.  
(d) Feature annotation: pathway enrichment analysis of CD-specific gene expression profiles. Gene Set Enrichment 
Analysis (GSEA) is an open-access software that computes the degree of overlap between a predefined gene set and 
collection of annotated gene sets in the Molecular Signatures Databases (MSigDB) [Subramanian 2005]. We use this 
tool to search for enriched Reactome and molecular function pathways among the CD-associated genes. 
(e) Independent in silico replication in general cell line model systems. A panel 64 human-derived general cell line 
models, measuring 12,073 gene expression features, from the Human Cell Atlas [Thul 2017] served as independent 
in silico replication. (https://www.proteinatlas.org/download/rna_celline.tsv.zip)  We performed a correlation test of 
the counts in each specific cell types sample between that gene and its corresponding CD expression on features 
identified during feature selection stage 2. 
Results 
(a) Assembly of SLE Compendium. Our compendium of human SLE patients contained 1,576 observations, with 
multiple measures per patient, aggregated from original studies [Chaussabel 2008, Lauwerys 2013, Ducreux 2016, 
Chiche 2014, Carpintero 2015, Banchereau 2016, Welcher 2015]. The SLE compendium contained 15,497 gene 
expression measurements with observations from healthy control (n=160) samples, treatment-naïve SLE (n=1,290) 
samples, and SLE samples exposed to various treatments (n=126) (Table 1).  
(b) Feature selection stage 1 – Gene expression profile of treatment naïve SLE patients. In our study, maximizing 
prediction balanced model accuracy was only a minor component of our gene expression profiling, with maximizing 
opportunity for biologically rich and inferential signals being of most importance. Further complicating gene 
expression profiling endeavors was the known issue possibility of multicollinearity, where many biologically 
important signals are correlated with both other explanatory features and the study outcomes. Therefore, selection of 
the mathematically robust model MultiSURF with an inclusive, albeit replicable, feature inclusion threshold of 0.177 
(1500/max(raw feature score)) was chosen based on the distribution of the importance scores [Supplement 1. Figure 
S1]. This heuristic threshold yields a reasonable number of genes for the next step of the analysis. Applying this 
threshold, we collected p=681 gene expression features that have significantly high total importance score compared 
to the remaining genes. We reiterate that rescaling the MultiSURF importance scores to range from -1 to 1 does not 
affect the relative importance among features.  
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Table 1. SLE Compendium characteristics as ascertained from study of origin  
 Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Cohort 6 Overall 
Study PMID 18631455 23203821 24644022 25736140 27040498 26138472 --- 
Study GEO identifier GSE11907 GSE39088 GSE49454 GSE61635 GSE65391 GSE78193 --- 
Healthy control* 0 46 0 30 72 12 160 
median age (range) --- 34.5  (19-50) --- --- 
12 
(6-21) --- 
16  
(6-50) 
gender - female/male --- 34 --- --- 57 --- 91 
SLE-treatment naïve* 37 21 177 99 924 32 1290 
median age (range) 14 (8-17) 
43 
(20-50) 
40 
(18-71) --- 
15 
(6-19) --- 
16 
(6-71) 
gender - female 35 21 148 --- 817 --- 1021 
SLE-various 
treatments* 0 57 0 0 0 69 126 
median age (range) --- 36 (19-50) --- --- --- --- 
36 
(19-50) 
gender - female/male --- 57 --- --- --- --- 57 
*observation characteristics represent multiple observations per patient 
Figure 2. Gene expression feature importance profile of treatment naïve systemic lupus erythematosus patients 
(top 100 features listed). Results from step b, containing 681 gene expression features that differentiate treatment 
naïve SLE patients from healthy controls and SLE patients exposed to various treatment. Feature importance profile 
includes: i) scaled importance score (grey bars) and ii) corresponding out-of-sample classification accuracy of sample 
type (HC/SLE treatment naïve/SLE treatment) from adjusted TPOT-recommended pipeline with iterative inclusion of 
features from left to right (orange, blue or green lines). The y-axis represents both the MultiSURF scaled importance 
score and TPOT pipeline accuracy. 
We noted that our focus at the first stage of the analysis is feature inclusion; therefore, we only reported the 
performance from the optimized pipeline as an estimation of the model’s predictive power. TPOT suggested a complex 
pipeline that stacks the gradient boosting, decision tree and Random Forest algorithm with an intermediate step of 
selecting the top 20-percentile features based on their ANOVA F-values between with the class. We adjusted the 
TPOT-recommended pipeline slightly by removing one step of feature selection in order to obtain the corresponding 
out of sample accuracy as we include more features in the stacked model (Figure 2). Initially, as more predictors were 
included in the model, the out of sample accuracy increased, demonstrating that the added features are meaningful. 
However, we note that after the inclusion of approximately ten most predictive features in the model, the increase in 
balanced accuracy (yellow) and Kappa coefficient (blue) slowed down. Nevertheless, there was an overall upward 
trend in these performance metric values as more features were added to the model. We also noted that the flow of 
balanced accuracy and Kappa coefficient are not smooth, which was likely due to the built-in stochasticity of the 
model. To prevent any biases in the feature scoring metric of the algorithm, we consider all 681 genes for the second 
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stage of finding association with CD expression. We note that the 681-predictor model attains a relatively high out-
of-sample prediction accuracy of approximately 0.935, balanced accuracy of 0.822, and Kappa coefficient of 0.680. 
We recalled the Kappa coefficient is an accuracy measure that is scaled to expected accuracy which is the random 
chance of making a correct prediction by a null model. In particular, a Kappa coefficient of 0.680 means that the model 
achieved a rate of classification 68% of the way between a null model and perfect classification. 
(c) Feature selection stage 2 – CD-specific gene expression profiles. Within the 681 features selected during (b) 
feature selection stage 1, elastic net regularized binomial logistic regression model to select features that are 
statistically associated with select CDs and calculated the binomial deviance D, the conventional measure of the lack 
of fit to the data in a logistic regression model. Fixing the hyper-parameter α=0.5, we used cross-validation to tune the 
regularization parameter λ. Overall, the regularized logistic regression achieved high correlation with CD20 
(D=0.0698, λ=0.0335, k=53 features), CD22 (D=0.1351, λ=0.0310, k=78 features), and CD30 (D=0.1908, λ=0.0221, 
k=137 features). Selected gene expression features were then characterized as univariate associations (i.e. independent 
effects) on the same CD endpoints. Gene expression features, in addition to corresponding effect size and significance, 
varied widely between CD20, CD22, and CD30 (Figure 3). Odds ratios and 95% confidence intervals characterize 
increasing explanatory gene expression unless designated otherwise (*=decreasing explanatory gene expression). 
Even though independent analyses do not reveal the significance of several genes (95% CI of odds ratio well contains 
the null value of 1, such as MARCKSL), they are kept in the elastic net algorithm due to their contribution to the 
amount of variance explained in the regression model. We note that the odds ratios and their 95% CI are shown without 
including study origin as a covariate due to relative consist distribution of CD expression across the compendium 
studies [Supplement 2. Figure S2]. However, we performed additional regressions to explore a potential study of 
origin effect, and only the regression of CD30 aberrant expression level suggested a potential difference between 
GSE49454/GSE61635 and the remaining studies [Supplement 3. Figure S3]. For consistency, we showed the results 
from simple regressions with only one explanatory variable (gene expression).  
(d) Feature annotation: pathway enrichment analysis of CD-associated genes. We performed GSEA of molecular 
function and biological processes amongst features recommended by feature selection stage 2 to enhance our de novo 
profile with existing knowledge bases. Our motivation was two-fold: i) We recognized that by study design, feature 
selection stage 1 – gene expression profile of treatment naïve SLE patients had potential to introduce false negatives 
into CD-specific profiles due to reduction of the feature space, and ii) while biological activity typically consists of 
tightly-connected reactions and interactions, statistical signals might be too disparate to clearly resonate within 
existing biological knowledge.  
Our GSEA identified several noteworthy findings within biological processes: Phosphate-containing compound 
metabolic process was identified for CD22 (k/K=0.0076, 1.94e-3, encompassing: DLG1, DUSP15, EPHB4, IKBKAP, 
MAP2K6, MSH2, NDUFB1, NUDT5, PDE8A, PDGFB, PHOSPHO1, RFK, TNK2, TTN, and TYMP) and CD30 
(k/K=0.0086, 1.53e-2, encompassing: ABHD14B, IRS1, ISYNA1, MAP2K6, ME1, NDUFB1, OBSCN, PANK3, 
PDE8A, PDGFB, PHOSPHO1, PI4K2A, PRKD3, PSMB4, RIPK3, SMPD3, and TNK2). The closely-related 
organophosphate metabolic process was also identified for CD22 (k/K=0.0076, 1.94e-3, encompassing: DLG1, 
MSH2, NDUFB1, NUDT5, PDE8A, PDGFB, PHOSPHO1, RFK, TYMP) and CD30 (k/K=0.0076, 1.94e-3, 
encompassing: ABHD14B, IRS1, ISYNA1, ME1, NDUFB1, PANK3, PDE8A, PDGFB, PHOSPHO1, PI4K2A, and 
SMPD3). Kinase activity, catalysis a phosphate group to a substrate molecule, for CD22 (k/K=0.0083, q=3.64e-2, 
encompassing: ACSL6, ABCB4, ATN1, BAG2, CEP68, EIF3L, IKBKAP). 
For CD20, several signals broadly encompassing tissue development and function were identified, including: muscle 
contraction (k/K=0.0172, q=4.79e-2), muscle organ development (k/K=0.0181, q=2.57e-2), muscle structure 
development (k/K=0.0116, q=4.79e-2), muscle system process (k/K=0.0177, q=2.57e-2), organ morphogenesis 
(k/K=0.0083, q=3.80e-2). Calmodulin binding, implicating intracellular calcium receptor regulation, was also linked 
to CD20 (k/K=0.0279, q=1.14e-3, encompassing: SCN5A, USP6, TTN, MYH3, MARCKSL1). Calmodulin affects a 
wide range of physiological processes, including cell proliferation, apoptosis, autophagy, and cancer cell 
differentiation [Berchtold 2014]. Detailed associations are provided for the cellular function [Supplement 4. Table 
S1.] and molecular pathways [Supplement 5. Table S2.] gene enrichment analyses. 
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Figure 3. Gene expression biomarker profile of CD aberrance. 
Statistical annotation of features recommended by integrative analyses  as 
characterizing CD aberrance: i) MultiSURF being predictive of SLE 
patients, and ii) amongst treatment naive SLE patients, regularized logistic 
regression as being associated with aberrant CD biomarker expression. 
Interpretation: Risk [odds ratio (95% CI)] of going from normal CD gene 
expression to aberrant CD gene expression (Figure 3), modeled 
independently by logistic regression. Direction of expression is denoted in 
blue (Increase) or orange (Decrease). For example, as predictor NRCAM 
normalized gene expression value decreases by 0.1, the risk of aberrant 
CD22 gene expression increases by 1.24.  
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(e) Independent in silico replication of CD-specific gene expression profile in general cell model systems. We 
performed a correlation test between the transcript counts of the detected CD-associated genes with the corresponding 
CD in 64 human-derived cell lines. Among 78 gene expression features that were previously selected by elastic net to 
be associated with aberrant level of CD22, we found three genes, BCL7A, STRBP and PHOSPHO1, that have 
statistically significant correlation with the CD22 expression level in the Human Protein Atlas cell line database, after 
adjusting the p-values with the Benjamini-Hochberg’s procedure [Benjamini 2001]. For CD30, among 137 gene 
expression features that were identified by elastic net, four genes were shown to significantly correlate with the CD 
expression level: NCOA2, PHOSPHO1, ATN1, and HOXC4. None of the 53 CD20-related genes showed significant 
correlation in this cell line database after p-value correction.  
Table 2. In silico replication of features affecting CD aberrance in human-derived cell line models  
 Gene Correlation (95% CI) t-statistic 
Unadjusted 
p-value 
Adjusted  
p-value 
CD22 BCL7A 0.719 (0.575, 0.820) 8.14 2.25e-11 1.69e-9 
 STRBP 0.672 (0.510, 0.787) 7.14 1.23e-9 4.63e-8 
 PHOSPHO1  (0.152, 0.575 3.27 1.75e-3 4.37e-2 
       
CD30 NCOA2 0.534 (0.331, 0.689) 4.97 5.58e-6 7.00e-4 
 PHOSPHO1 0.464 (0.246, 0.637) 4.12 1.13e-4 7.40e-3 
 ATN1 0.430 (0.206, 0.611) 3.75 3.88e-4 1.71e-2 
 HOXC4 0.401 (0.173, 0.589) 3.45 1.01e-3 3.34e-2 
 
Discussion  
Using the i-mAB pipeline we identified several noteworthy findings that enrich our understanding of CD biology: For 
CD22 and CD30 we found phosphate-containing compound metabolic process, organophosphate metabolic process, 
kinase activity (phosphate catalysis). In independent in silico replication, PHOSPHO1, a phosphatase linked to bone 
mineralization, was associated with both CD22 and CD30 gene expression. Future in vitro study is warranted to 
elucidate the potential implication of phosphates on aberrant CD22 and CD30 expression. For CD20, several signals 
broadly encompassing tissue development and function were identified, including: muscle contraction muscle organ 
development, muscle structure development, muscle system process, organ morphogenesis, and most interestingly, 
calmodulin binding (intracellular calcium receptor regulation). 
Strength and limitation. Aggregation of public datasets may provide a number of advantages but also disadvantages 
including potential bias due to study origin. However, we closely followed the guideline suggested by Smith et al. in 
analyzing secondary datasets to produce meaningful results [Smith 2011] and paid close attention to the aggregation 
procedure to minimize potential bias across studies. We utilized robust methodologies, careful selected models, and 
sound analytical comparisons to identify gene expression signals with potential for biological relevance. In our study, 
two key methodological considerations existed, encompassing three parts: i) initial gene expression feature generation 
(i.e. feature selection stage 1) representative of treatment naive SLE patients and ii) attribution of features (i.e. feature 
selection stage 2) to CDs as gene expression profiles, and iii) feature annotation. i) In pursuit of developing an agnostic 
gene expression profile of treatment naive SLE patients, we were required to make imbalanced comparisons between 
healthy normal controls (n=160) and treated SLE patients (n=126) to treatment naive SLE patients (n=1,290). 
However, we took a series of steps to overcome potential limitations due to imbalanced comparisons. First, 
MultiSURF, a feature selection method known to be robust to imbalanced data, served as our agnostic feature 
generator and identified gene expression features of potential relevance. Second, an automated machine learning 
system recommended an optimized pipeline with multiple complex algorithms that would not have been implemented 
manually without automated machine learning. We focused on the completeness of measures of the model’s 
performance and reported the Cohen’s Kappa coefficient as well as balanced accuracy while considering the multi-
class and imbalanced-class problems. ii) From a statistical perspective, gene expression can be highly correlated 
potentially because the perspective of the aggregate transcriptome might be indiscriminate to complex biological 
synthesis and regulatory pathways influencing gene expression. We applied a regularized multivariate logistic 
regression to identify the predictive features that are statistically significantly associated with the aberrant level of 
CDs expression while taking into account the data’s multicollinearity. iii) Univariate associations between individual 
gene expression features and select CDs were independently tested. However, considering the interaction among the 
genes, we focused on the pathway enrichment analysis of CD-associated genes. We highlighted certain single gene 
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expression features due to transparent biological relevance and confidence in strength of signal. Further, the 
independent in silico replication of the several CD-specific gene expression profiles in general cell model systems 
also ascertained the association between these genes and the CD expression. Incorporating a priori hypotheses in 
newly developed, data-driven machine learning methods, i-mAB provides a biologically scalable pipeline for profiling 
CDs and potentially other interdependent biomarkers such as cytokines. 
Consideration for generalizability. Some protein products degrade rapidly while others are persistent for a long time. 
Similarly, transcripts are known to have dramatic variation in persistence - elevated transcript levels might be 
necessary to produce comparable levels of bioavailable protein products in comparison to more stable proteins (e.g. 
proteins within the same pathways). Aberrant biology occurring within the SLE disease state has potential to 
indeterminately modify transcript synthesis or protein bioavailability (i.e. stability, degradation) and maintenance of 
physiological homeostasis. A single statistical or machine learning approach often provides a wide-angle view of the 
biological picture of disease. Careful iterative analysis with multiple approaches may provide a higher resolution 
picture of complex mechanism and signals of disease. While the signals replicated within general cell model systems 
potentially suggest broader biological implications, these biomarkers might have limited application to whole blood 
and B-lymphocytes. As previously noted, a subset of patients labeled as treatment naïve likely received maintenance 
immunosuppressive therapy. Although the therapy was not an active treatment for the disease, it may have slightly 
attenuated the overall transcriptome expression. Replication of the pathway findings and independent replication 
signals are warranted for different diseases and tissue-specific environments 
Potential biomarker applications of upstream biological features as potential biomarkers. CDs may represent 
biological relevant markers of disease. Due to orphan drug policy [Braun 2010], enriched CD perspectives might 
stimulate opportunities for therapeutic repositioning across disease with similar biomarker expression. Particularly for 
treatment of rare diseases [Seoane 2008] therapeutic mABs have been previously demonstrated to be safe in humans. 
Conclusion 
The i-mAB pipeline identified novel (adjusted independent) associations of potential relevance to CD biology: BCL7A 
(p=1.69e-9) and STRBP (p=4.63e-8) with CD22; NCOA2(p=7.00e-4), ATN1(p=1.71e-2), and HOXC4 (p=3.34e-2) 
with CD30.  PHOSPHO1, a phosphatase linked to bone mineralization, was associated with both CD22 (p=4.37e-2) 
and CD30 (p=7.40e-3) expression. Simultaneously leveraging a priori hypotheses, performing secondary data 
analysis, and integrating appropriate machine learning approaches, i-mAB provides opportunity to detect de novo gene 
expression features that replicate in independent disease-agnostic model systems and enrich our understanding of the 
molecular characteristics of SLE and select CDs. 
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Supplement 1. Figure S1. Sorted MultiSURF feature importance scores of all gene expression features.  
 
 
Figure S1. Feature importance threshold of 0.177 was selected heuristically based on the distribution of scores. The 
681 gene expression features (yellow) above this threshold were selected for inclusion within the gene expression 
profile of SLE, treatment naïve patients. 
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Supplement 2. Figure S2. Distribution of CD20, CD22, & CD30 gene expression by original study cohort 
 
 
Figure S2. Boxplots and 95% confidence intervals of normalized gene expression for CD20, CD22, and CD30 on a 
scale of 0 – 1. Only minor variation was observed between original study cohorts.  
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Supplement 3. Figure S3. Batch effect characterization for CD20, CD22, & CD30 
 
 
 
 
Figure S3. Boxplots and 95% confidence intervals of log10 p-values comparing original study cohort (GSE ID 
provided) to GSE11907. A potential batch (cohort) effect was denoted for GSE49454 and GSE61635 for CD30. 
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Supplement 4. Table S1. Cellular function gene sets. 
CD 
Predictor Gene Set Name 1 Gene Set Description k / K 2 p-value 3 
FDR 4  
q-value Genes contained within set overlap 
CD20 Actin-mediated cell contraction 
The actin filament-based process in which 
cytoplasmic actin filaments slide past one 
another resulting in contraction of all or part of 
the cell body. 
3 / 74 6.58E-05 4.79E-02 SCN5A, TTN, MYH3 
CD20 
Enyzme linked 
receptor protein 
signaling pathway 
Any series of molecular signals initiated by the 
binding of an extracellular ligand to a receptor 
on the surface of the target cell, where the 
receptor possesses catalytic activity or is 
closely associated with an enzyme such as a 
protein kinase, and ending with regulation of a 
downstream cellular process, e.g. transcription. 
6 / 689 7.98E-05 4.79E-02 FOXH1, MEGF8, PDGFB, EFNB1, ATP6V1G2, GUCA1B 
CD20 Glycoprotein catabolic process 
The chemical reactions and pathways resulting 
in the breakdown of glycoproteins, any protein 
that contains covalently bound glycose (i.e. 
monosaccharide) residues; the glycose occurs 
most commonly as oligosaccharide or fairly 
small polysaccharide but occasionally as 
monosaccharide. 
2 / 15 1.11E-04 4.79E-02 CELA1, FBXO6 
CD22 Immune response 
Any immune system process that functions in 
the calibrated response of an organism to a 
potential internal or invasive threat. 
11 / 1100 1.48E-06 2.00E-03 
DLG1, GPR183, HLA-DQB1, 
IKBKAP, MSH2, MT2A, 
PGLYRP2, PXDN, TNK2, TRAF3, 
TRPM4 
CD22 Immune system process 
Any process involved in the development or 
functioning of the immune system, an 
organismal system for calibrated responses to 
potential internal or invasive threats. 
14 / 1984 2.98E-06 2.00E-03 
ABCB4, DLG1, GPR183, HLA-
DQB1, IKBKAP, MAP2K6, MSH2, 
MT2A, PDGFB, PGLYRP2, , 
PXDN, TNK2, TRAF3, TRPM4 
CD30 
Intracellular 
signal 
transduction 
The process in which a signal is passed on to 
downstream components within the cell, which 
become activated themselves to further 
propagate the signal and finally trigger a 
change in the function or state of the cell. 
15 / 1572 2.82E-05 1.53E-02 
GPR182, IRS1, MAP2K6, NKX3-1, 
PDGFB, PRKD3, PSMB4, RAB3A, 
RIPK3, SART1, STAT2, TMBIM6, 
TNK2, TP63, ZMAT3 
CD22 Mechanosensory behavior 
Behavior that is dependent upon the sensation 
of a mechanical stimulus. 3 / 12 8.73E-07 1.94E-03 CNTNAP2, NRXN2, STRBP 
CD20 Membrane depolarization 
The process in which membrane potential 
decreases with respect to its steady-state 
potential, usually from negative potential to a 
more positive potential. For example, the 
initial depolarization during the rising phase of 
an action potential is in the direction from the 
negative steady-state resting potential towards 
the positive membrane potential that will be 
the peak of the action potential. 
3 / 61 3.69E-05 4.09E-02 SCN5A, CACNA1H, CASP1 
CD22 Membrane organization 
A process which results in the assembly, 
arrangement of constituent parts, or 
disassembly of a membrane. A membrane is a 
double layer of lipid molecules that encloses 
all cells, and, in eukaryotes, many organelles; 
may be a single or double lipid bilayer; also 
includes associated proteins. 
10 / 899 1.81E-06 2.00E-03 
ABCB4, CNTNAP2, DLG1, 
NRCAM, NRXN2, RAPGEF6, 
RPL14, , RPL15, RPS23, SGCE 
CD22 Multi-organism metabolic process 
A metabolic process - chemical reactions and 
pathways, including anabolism and catabolism, 
by which living organisms transform chemical 
substances - which involves more than one 
organism. 
5 / 138 3.10E-06 2.00E-03 EIF3L, MAP2K6, RPL14, RPL15, RPS23 
CD20 Muscle contraction 
A process in which force is generated within 
muscle tissue, resulting in a change in muscle 
geometry. Force generation involves a chemo-
mechanical energy conversion step that is 
carried out by the actin/myosin complex 
activity, which generates force through ATP 
hydrolysis. 
4 / 233 1.05E-04 4.79E-02 TTN, MYH3, CACNA1H, SCN5A 
CD20 Muscle organ development 
The process whose specific outcome is the 
progression of the muscle over time, from its 
formation to the mature structure. The muscle 
is an organ consisting of a tissue made up of 
various elongated cells that are specialized to 
contract and thus to produce movement and 
mechanical work. 
5 / 277 1.06E-05 2.57E-02 TTN, CACNA1H, MYH3, SGCE, FOXH1 
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CD20 Muscle structure development 
The progression of a muscle structure over 
time, from its formation to its mature state. 
Muscle structures are contractile cells, tissues 
or organs that are found in multicellular 
organisms. 
5 / 432 8.81E-05 4.79E-02 FOXH1, TTN, MYH3, CACNA1H, SGCE 
CD20 Muscle system process 
A organ system process carried out at the level 
of a muscle. Muscle tissue is composed of 
contractile cells or fibers. 
5 / 282 1.16E-05 2.57E-02 TTN, CACNA1H, MYH3, SGCE, SCN5A 
CD30 
Negative 
regulation of 
nitrogen 
compound 
metabolic process 
Any process that stops, prevents, or reduces the 
frequency, rate or extent of the chemical 
reactions and pathways involving nitrogen or 
nitrogenous compounds. 
15 / 1517 1.87E-05 1.38E-02 
ADAR, ATN1, BAHD1, BCL7A, 
CELA1, NANOS1, NCOA2, NKX3-
1, NOC2L, PDGFB, PTCH1, 
TMBIM6, TP63, TRIM22, ZNF93 
CD30 
Negative 
regulation of 
protein complex 
assembly 
Any process that stops, prevents, or reduces the 
frequency, rate or extent of protein complex 
assembly. 
5 / 107 1.22E-05 1.38E-02 CLIP3, KANK1, PFN2, VILL, XAF1 
CD30 
Negative 
regulation of 
protein 
polymerization 
Any process that stops, prevents, or reduces the 
frequency, rate or extent of the process of 
creating protein polymers. 
4 / 55 1.65E-05 1.38E-02 CLIP3, KANK1, PFN2, VILL 
CD30 
Negative 
regulation of 
response to 
stimulus 
Any process that stops, prevents, or reduces the 
frequency, rate or extent of a response to a 
stimulus. Response to stimulus is a change in 
state or activity of a cell or an organism (in 
terms of movement, secretion, enzyme 
production, gene expression, etc.) as a result of 
a stimulus. 
15 / 1360 5.17E-06 1.38E-02 
ADAR, DHX58, IRS1, KANK1, 
NKX3-1, NOC2L, PDGFB, PSMB4, 
PTCH1, PXDN, SH3BP4, TMBIM6, 
TNFAIP6, TP63, TXNDC12 
CD20 Organ morphogenesis 
Morphogenesis of an organ. An organ is 
defined as a tissue or set of tissues that work 
together to perform a specific function or 
functions. Morphogenesis is the process in 
which anatomical structures are generated and 
organized. Organs are commonly observed as 
visibly distinct structures, but may also exist as 
loosely associated clusters of cells that work 
together to perform a specific function or 
functions. 
7 / 841 2.57E-05 3.80E-02 TTN, SCN5A, FOXH1, TP63, DLG5, MEGF8, CELA1 
CD22 
Organonitrogen 
compound 
metabolic process 
The chemical reactions and pathways 
involving organonitrogen compound. 13 / 1796 5.38E-06 2.98E-03 
DLG1, EIF3L, MSH2, NDUFB1, 
PDE8A, PGLYRP2, PHOSPHO1, 
RFK, RNF180, RPL14, RPL15, 
RPS23, TYMP 
CD22 Organophosphate metabolic process 
The chemical reactions and pathways 
involving organophosphates, any phosphate-
containing organic compound. 
9 / 885 1.26E-05 5.62E-03 
DLG1, MSH2, NDUFB1, NUDT5, 
PDE8A, PDGFB, PHOSPHO1, RFK, 
TYMP 
CD30 Organophosphate metabolic process 
The chemical reactions and pathways 
involving organophosphates, any phosphate-
containing organic compound. 
11 / 885 3.46E-05 1.54E-02 
ABHD14B, IRS1, ISYNA1, ME1, 
NDUFB1, PANK3, PDE8A, 
PDGFB, PHOSPHO1, PI4K2A, , 
SMPD3 
CD22 Peptidyl tyrosine modification The modification of peptidyl-tyrosine. 5 / 186 1.32E-05 5.62E-03 
EPHB4, MAP2K6, PDGFB, TNK2, 
TTN 
CD22 
Phosphate-
containing 
compound 
metabolic process 
The chemical reactions and pathways 
involving the phosphate group, the anion or 
salt of any phosphoric acid. 
15 / 1977 5.03E-07 1.94E-03 
DLG1, DUSP15, EPHB4, IKBKAP, 
MAP2K6, MSH2, NDUFB1, 
NUDT5, PDE8A, PDGFB, 
PHOSPHO1, RFK, TNK2, TTN, 
TYMP 
CD30 
Phosphate-
containing 
compound 
metabolic process 
The chemical reactions and pathways 
involving the phosphate group, the anion or 
salt of any phosphoric acid. 
17 / 1977 2.99E-05 1.53E-02 
ABHD14B, IRS1, ISYNA1, 
MAP2K6, ME1, NDUFB1, OBSCN, 
PANK3, PDE8A, PDGFB, 
PHOSPHO1, PI4K2A, PRKD3, 
PSMB4, RIPK3, SMPD3, TNK2 
CD20 
Polarized 
epithelial cell 
differentiation 
The process in which a relatively unspecialized 
cell acquires specialized features of a polarized 
epithelial cell. The polarized epithelial cell can 
be any of the cells within an epithelium where 
the epithelial sheet is oriented with respect to 
the planar axis. 
2 / 12 7.00E-05 4.79E-02 TP63, DLG5 
CD30 
Positive 
regulation of 
transport 
Any process that activates or increases the 
frequency, rate or extent of the directed 
movement of substances (such as 
macromolecules, small molecules, ions) into, 
out of or within a cell, or between cells, by 
means of some agent such as a transporter or 
pore. 
12 / 936 1.11E-05 1.38E-02 
CASP1, CLIP3, IRS1, KANK1, 
MAP2K6, NKX3-1, PDGFB, 
PTCH1, RAB3A, SMPD3, TP63, 
TRPM4 
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CD30 
Regulation of 
intracellular 
signal 
transduction 
Any process that modulates the frequency, rate 
or extent of intracellular signal transduction. 16 / 1656 1.28E-05 1.38E-02 
ANKRD54, CASP1, DHX58, IRS1, 
KANK1, MAP2K6, NKX3-1, 
NOC2L, OBSCN, PDGFB, RIPK3, 
SH3BP4, TMBIM6, TP63, TRIM22, 
TXNDC12 
CD22 
Regulation of 
protein 
modification 
process 
Any process that modulates the frequency, rate 
or extent of the covalent alteration of one or 
more amino acid residues within a protein. 
13 / 1710 3.16E-06 2.00E-03 
DLG1, DUSP15, GADD45B, 
GPR183, IKBKAP, MAP2K6, 
NKX3-1, PDGFB, PKIG, RNF180, 
TADA2A, TNK2, TTN 
CD30 
Ribonucleoprotein 
complex 
biogenesis 
A cellular process that results in the 
biosynthesis of constituent macromolecules, 
assembly, and arrangement of constituent parts 
of a complex containing RNA and proteins. 
Includes the biosynthesis of the constituent 
RNA and protein molecules, and those 
macromolecular modifications that are 
involved in synthesis or assembly of the 
ribonucleoprotein complex. 
8 / 440 3.11E-05 1.53E-02 ADAR, EIF3L, NOC2L, RPL3, RPS17, RPS23, SART1, SENP3 
 
1 – Biological processes pathways as defined by Gene Ontology 
2 – The overlap ratio k/K is show the number of genes in the overlap (k), by the total number of genes in the gene set (K) 
3 – Unadjusted p-value calculated from the hypergeometric probability distribution 
4 – Adjusted p-value using the Benjamini-Hochberg procedure with FDR 
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Supplement 5. Table S2. Molecular pathways involved in CD-related gene sets. 
CD 
Predictor 
Gene Set  
Name 1 Gene Set Description k / K 2 p-value 3 
FDR 4  
q-value Genes contained within set overlap 
CD30 Adenosine deaminase activity 
Catalysis of the reaction: adenosine + H2O 
= inosine + NH3. 2 / 11 4.04E-04 3.39E-02 ADAR, ZBP1 
CD22 Adenyl nucleotide binding 
Interacting selectively and non-covalently 
with adenyl nucleotides, any compound 
consisting of adenosine esterified with 
(ortho)phosphate. 
12 / 1514 5.20E-06 2.34E-03 
ACSL6, ABCB4, BAG2, CHD9, DDX54, 
EPHB4, MAP2K6, MSH2, RFK, TTN, 
TRPM4, TNK2 
CD30 Adenyl nucleotide binding 
Interacting selectively and non-covalently 
with adenyl nucleotides, any compound 
consisting of adenosine esterified with 
(ortho)phosphate. 
17 / 1514 9.05E-07 2.04E-04 
ACSL6, BBS12, DHX58, DYNC1LI1, 
KATNAL1, MAP2K6, ME1, OBSCN, 
PANK3, PFN2, PI4K2A, PMS1, PRKD3, 
QARS, RIPK3, TNK2, TRPM4 
CD20 Calmodulin binding 
Interacting selectively and non-covalently 
with calmodulin, a calcium-binding protein 
with many roles, both in the calcium-bound 
and calcium-free states. 
5 / 179 1.27E-06 1.14E-03 SCN5A, USP6, TTN, MYH3, MARCKSL1 
CD22 Enzyme binding Interacting selectively and non-covalently with any enzyme. 14 / 1737 6.27E-07 5.65E-04 
ACSL6, CEP68, CNTNAP2, DLG1, FBL, 
IKBKAP, MAP2K6, MSH2, NKX3-1, 
RAPGEF6, RNF180, SGSM1, TRAF3, TTN 
CD22 Kinase activity 
Catalysis of the transfer of a phosphate 
group, usually from ATP, to a substrate 
molecule. 
7 / 842 4.20E-04 3.64E-02 ACSL6, ABCB4, ATN1, BAG2, CEP68, EIF3L, IKBKAP 
CD30 Macromolecular complex binding 
Interacting selectively and non-covalently 
with any macromolecular complex. 17 / 1399 3.05E-07 1.43E-04 
ANKRD54, BAHD1, CLIP3, GNA11, GNAL, 
IRS1, KATNAL1, KLHL17, MAPRE3, 
NCOA2, NOC2L, PDGFB, PI4K2A, PTCH1, 
RIPK3, TADA2A, TP63 
CD22 Molecular function regulator 
A molecular function that modulates the 
activity of a gene product or complex.  
Examples include enzyme regulators and 
channel regulators. 
11 / 1353 1.06E-05 3.18E-03 
BAG2, DLG1, IKBKAP, NRXN2, NKX3-1, 
PXDN, PDGFB, PKIG, RAPGEF6, SGSM1, 
TNK2 
CD30 Molecular function regulator 
A molecular function that modulates the 
activity of a gene product or complex.  
Examples include enzyme regulators and 
channel regulators. 
14 / 1353 2.21E-05 3.31E-03 
ANKRD54, CASP1, IRS1, NCOA2, NKX3-1, 
NRXN2, OBSCN, PDGFB, PFN2, PXDN, 
RAB3A, SH3BP4, TMBIM6, TNK2 
CD30 
Nucleic acid 
binding 
transcription factor 
activity 
Interacting selectively and non-covalently 
with a DNA or RNA sequence in order to 
modulate transcription. The transcription 
factor may or may not also interact 
selectively with a protein or macromolecular 
complex. 
12 / 1199 1.20E-04 1.47E-02 
HOXC4, NKX3-1, STAT2, TADA2A, TP63, 
TRIM22, ZNF134, ZNF420, ZNF561, 
ZNF606, ZNF79, ZNF93 
CD22 
Platelet-derived 
growth factor 
receptor binding 
Interacting selectively and non-covalently 
with the platelet-derived growth factor 
receptor. 
2 / 15 2.65E-04 2.65E-02 PDGFB, TYMP 
CD30 Protein complex binding 
Interacting selectively and non-covalently 
with any protein complex (a complex of two 
or more proteins that may include other 
nonprotein molecules). 
14 / 935 3.17E-07 1.43E-04 
ANKRD54, CLIP3, GNA11, GNAL, IRS1, 
KATNAL1, KLHL17, MAPRE3, NCOA2, 
NOC2L, PDGFB, PI4K2A, PTCH1, RIPK3 
CD22 Protein domain-specific binding 
Interacting selectively and non-covalently 
with a specific domain of a protein. 7 / 624 6.74E-05 1.52E-02 
ATN1, CEP68, DLG1, KLHL17, NKX3-1, 
RNF2, TNK2 
CD30 Protein domain-specific binding 
Interacting selectively and non-covalently 
with a specific domain of a protein. 10 / 624 9.32E-06 1.68E-03 
ATN1, HOXC4, IRS1, KHDRBS3, KLHL17, 
LIN7B, NCOA2, NKX3-1, TNK2, TP63 
CD22 Protein tyrosine kinase activity 
Catalysis of the reaction: ATP + a protein 
tyrosine = ADP + protein tyrosine 
phosphate. 
4 / 176 1.94E-04 2.19E-02 EPHB4, MAP2K6, TTN, TNK2 
CD22 Ribonucleotide binding 
Interacting selectively and non-covalently 
with a ribonucleotide, any compound 
consisting of a ribonucleoside that is 
esterified with (ortho)phosphate or an 
oligophosphate at any hydroxyl group on the 
ribose moiety 
11 / 1860 1.85E-04 2.19E-02 ACSL6, ABCB4, CHD9, DDX54, EPHB4, MAP2K6, MSH2, RFK, TTN, TRPM4, TNK2  
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CD30 Ribonucleotide binding 
Interacting selectively and non-covalently 
with a ribonucleotide, any compound 
consisting of a ribonucleoside that is 
esterified with (ortho)phosphate or an 
oligophosphate at any hydroxyl group on the 
ribose moiety. 
19 / 1860 8.02E-07 2.04E-04 
ACSL6, BBS12, DHX58, DYNC1LI1, 
GNA11, GNAL, KATNAL1, MAP2K6, ME1, 
OBSCN, PANK3, PI4K2A, PMS1, PRKD3, 
QARS, RAB3A, RIPK3, TNK2, TRPM4 
CD30 RNA binding Interacting selectively and non-covalently with an RNA molecule or a portion thereof. 14 / 1598 1.30E-04 1.47E-02 
ADAR, DHX58, DYNC1LI1, EIF3L, 
KHDRBS3, NANOS1, NOC2L, QARS, RPL3, 
RPS17, RPS23, SART1, ZBP1, ZMAT3 
CD22 Signal transducer activity 
Conveys a signal across a cell to trigger a 
change in cell function or state. A signal is a 
physical entity or change in state that is used 
to transfer information in order to trigger a 
response. 
11 / 1731 9.90E-05 1.78E-02 
EPHB4, GPR183, IKBKAP, LGR6, HLA-
DQB1, MAP2K6, NRXN2, NKX3-1, 
PGLYRP2, PLXNA3, TRAF3 
CD22 Structural molecule activity 
The action of a molecule that contributes to 
the structural integrity of a complex or 
assembly within or outside a cell. 
7 / 732 1.80E-04 2.19E-02 DLG1, KLHL17, PXDN, RPL14, RPL15, RPS23, TTN 
CD30 
Transcription 
factor activity 
protein binding 
Interacting selectively and non-covalently 
with any protein or protein complex (a 
complex of two or more proteins that may 
include other nonprotein molecules), in 
order to modulate transcription. A protein 
binding transcription factor may or may not 
also interact with the template nucleic acid 
(either DNA or RNA) as well. 
8 / 588 2.30E-04 2.30E-02 ATN1, NCOA2, NOC2L, PSMC3IP, RIPK3, TADA2A, TP63, TRIM22 
 
1 – Molecular functions pathways as defined by Gene Ontology 
2 – The overlap ratio k/K is show the number of genes in the overlap (k), by the total number of genes in the gene set (K) 
3 – Unadjusted p-value calculated from the hypergeometric probability distribution 
4 – Adjusted p-value using the Benjamini-Hochberg procedure with FDR 
 
 
 
 
